Table 2 Characteristics of treatment in the year before MASTERPLAN baseline in center A and B
|  | Center A (n = 98) | Center B (n = 82) | p |
|---|---|---|---|
No. of patient visits | 6.73 (6.21) | 3.11 (1.41) | <0.001 |
No. of different nephrologists/ internists | 1.92 (1.63) | 1.10 (0.30) | <0.001 |
No. of patient letters written | 0.70 (0.48) | 0.65 (0.51) | 0.43 |
No. of laboratory tests | Â | Â | Â |
 Serum calcium | 4.05 (4.31) | 2.39 (1.77) | 0.001 |
 Serum phosphate | 3.97 (4.14) | 2.30 (1.68) | 0.001 |
 Plasma PTH | 0.92 (1.48) | 1.01 (0.88) | 0.61 |
 Serum creatinine | 8.59 (9.80) | 5.32 (4.24) | 0.01 |
PTH level known | 60 (61%) | 58 (71%) | 0.18 |
 PTH exceeding recommended levels | 29 (30%) (n = 60) | 27 (47%) (n = 58) | 0.85 |
If PTH was exceeding recommended levels | (n = 29) | (n = 27) |  |
 Already on medication | 8 (28%) | 6 (22%) | 0.64 |
 Adjustment of treatment | 4 (14%) | 2 (7%) | 0.44 |
 Start treatment | 3 (10%) | 4 (15%) | 0.61 |
 PTH still exceeding recommended levels at MASTERPLAN baseline | 26 (90%) | 21 (78%) | 0.23 |
Change in serum creatinine (μmol/l) | 1.1 (31.1) | 8.2 (23.6) | 0.09 |
Hospitalization (at least once) | 22 (22%) | 12 (15%) | 0.18 |
Surgery (at least once) | 13 (13%) | 5 (6%) | 0.11 |